⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587064 | 0.83 | — | — | |
| SCHEMBL12743912 | 0.81 | — | — | |
| SCHEMBL21329241 | 0.81 | — | — | |
| SCHEMBL16004214 | 0.81 | — | — | |
| SCHEMBL21329239 | 0.81 | — | — | |
| SCHEMBL16004215 | 0.81 | — | — | |
| SCHEMBL16004221 | 0.81 | — | — | |
| SCHEMBL22645174 | 0.78 | — | — | |
| SCHEMBL21348253 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL31445288 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| EP-3939981-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3377501-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2021-08-18 | — | — | EP | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | LIFEARC (GB) | 2020-06-02 | — | — | US | disclosed |
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
| EP-2411009-B1 | Therapeutic uses of quinazolinedione derivatives | SANOFI SA (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |